Scientists found a new Alzheimer’s trigger and a drug that stops it
Researchers at ETH Zurich have identified a protein called GRK2 as a potential trigger for Alzheimer's disease and developed a compound that may slow its progression. The study, conducted on mice, shows that the compound prevents the accumulation of harmful protein clusters in nerve cells.
Why it matters
This discovery offers a new therapeutic target for Alzheimer's research, potentially leading to more effective treatments for dementia.
A promising experimental compound developed by researchers at ETH Zurich could offer a new way to slow the progression of Alzheimer's disease. In studies involving mice, the treatment reduced nerve cell loss, helped the animals live longer, and targeted a biological process that existing Alzheimer's drugs do not address.
The article is a straightforward summary of scientific research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in